PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21515370-9 2011 The numbers of both CD4(+) and CD8(+) cells were significantly suppressed in the blood of the recipients of both the FK506 and the TAK-779 groups, and in Peyer"s patches of the graft of the TAK-779 group, but the FK506 group was not, as evidenced by FACS analysis. Tacrolimus 117-122 Cd4 molecule Rattus norvegicus 20-23 30928512-6 2019 Compared with 0.05% tacrolimus eye drops, the in vivo immunofluorescence analysis indicated the tacrolimus loaded mPEG-b-PLGA micelles remarkably inhibit the immune rejection after corneal allograft, with the lower expression levels of nuclear factor of activated T cells (NFAT), cluster of differentiation 4 (CD4) and cluster of differentiation 8 (CD8). Tacrolimus 96-106 Cd4 molecule Rattus norvegicus 280-308 30928512-6 2019 Compared with 0.05% tacrolimus eye drops, the in vivo immunofluorescence analysis indicated the tacrolimus loaded mPEG-b-PLGA micelles remarkably inhibit the immune rejection after corneal allograft, with the lower expression levels of nuclear factor of activated T cells (NFAT), cluster of differentiation 4 (CD4) and cluster of differentiation 8 (CD8). Tacrolimus 96-106 Cd4 molecule Rattus norvegicus 310-313 21820512-9 2011 Reduced mRNA expression levels of CD4, IFN-gamma, IL-6, IL-10, iNOS, NFkappaB, TNF-alpha and MCP-1 (p <= 0.05) were observed in tacrolimus treated animals compared to sirolimus. Tacrolimus 131-141 Cd4 molecule Rattus norvegicus 34-37 21515370-9 2011 The numbers of both CD4(+) and CD8(+) cells were significantly suppressed in the blood of the recipients of both the FK506 and the TAK-779 groups, and in Peyer"s patches of the graft of the TAK-779 group, but the FK506 group was not, as evidenced by FACS analysis. Tacrolimus 213-218 Cd4 molecule Rattus norvegicus 20-23 18321198-9 2008 The rejected corneas in the FK506 nanosphere group showed significantly fewer CD4, CD8, CD68, CD79, vascular endothelial growth factor, ICAM, and tumor growth factor-beta(1)-positive cells than those in the other groups. Tacrolimus 28-33 Cd4 molecule Rattus norvegicus 78-81 20214743-6 2010 SBT allografts treated by FK506 and FTY720 demonstrated less infiltration of CD4 positive cells, but the irradiation group did not show any effects on its expression. Tacrolimus 26-31 Cd4 molecule Rattus norvegicus 77-80 20214743-9 2010 FK506 and FTY720 prevented the infiltration of CD4 positive cells, the down-regulation of MAdCAM-1 expression on HEVs in PPs, and the up-regulation of MAdCAM-1 expression on ECVs in LP during the early phase of SBT. Tacrolimus 0-5 Cd4 molecule Rattus norvegicus 47-50 19188906-8 2009 The increased Th1/Th2 ratio found in I/R livers after 2 h was reverted by immunosuppressants, which also amplified the proportion of CD4(+)CD25(+)Foxp3(+) regulatory T lymphocytes at 24 h. The protective effects of both tacrolimus and sirolimus correlated well with a decreased ratio of proinflammatory to anti-inflammatory T lymphocytes, and with an increase in the Treg proportion. Tacrolimus 220-230 Cd4 molecule Rattus norvegicus 133-136 17854565-9 2007 The levels of CD4(+) T cell subset in the peripheral blood of the tacrolimus-treated and tacrolimus plus TGP-treated groups were (38.71+/-5.15)% and (32.43+/-4.39)% respectively 7 days after transplantation. Tacrolimus 66-76 Cd4 molecule Rattus norvegicus 14-17 17854565-9 2007 The levels of CD4(+) T cell subset in the peripheral blood of the tacrolimus-treated and tacrolimus plus TGP-treated groups were (38.71+/-5.15)% and (32.43+/-4.39)% respectively 7 days after transplantation. Tacrolimus 89-99 Cd4 molecule Rattus norvegicus 14-17 17854565-10 2007 The level of CD4(+) T cell subset in the tacrolimus plus TGP-treated group was lower than that in the tacrolimus-treated group (P<0.05). Tacrolimus 41-51 Cd4 molecule Rattus norvegicus 13-16 17854565-10 2007 The level of CD4(+) T cell subset in the tacrolimus plus TGP-treated group was lower than that in the tacrolimus-treated group (P<0.05). Tacrolimus 102-112 Cd4 molecule Rattus norvegicus 13-16 11406149-5 2001 The expression of CD8alpha in mitogen-stimulated CD4(+) cells was blocked completely by calcineurin inhibitors (cyclosporine A and FK-506), and partially by rapamycin and SDZ-RAD. Tacrolimus 131-137 Cd4 molecule Rattus norvegicus 49-52 17275526-5 2007 RESULTS: After treatment with FK506, the proportion of CD4(+) cells significantly increased in the spleen at 12 hours, decreasing to control levels at 24 and 48 hours. Tacrolimus 30-35 Cd4 molecule Rattus norvegicus 55-58 17275526-8 2007 CONCLUSIONS: These results indicated that FK506 increased CD4(+) spleen lymphocyte activation in a short time, inducing a subsequent increase in CD4(+) cells subsets in peripheral blood. Tacrolimus 42-47 Cd4 molecule Rattus norvegicus 58-61 17275526-8 2007 CONCLUSIONS: These results indicated that FK506 increased CD4(+) spleen lymphocyte activation in a short time, inducing a subsequent increase in CD4(+) cells subsets in peripheral blood. Tacrolimus 42-47 Cd4 molecule Rattus norvegicus 145-148 14550820-7 2003 RESULTS: CsA and FK 506 reduced the presence graft-infiltrating leukocytes (CD4, CD8, CD11a, CD18) in the PVS of intra- and epicardial arteries when compared with control animals. Tacrolimus 17-23 Cd4 molecule Rattus norvegicus 76-79 8822088-5 1996 FK506 treatment suppressed the accumulation of ED-1-positive cells, CD4-positive cells, CD8-positive cells, interleukin-2 (IL-2)-receptor-positive cells, leukocyte-function-associated antigen-1 (LFA-1)-positive cells and intercellular adhesion molecule-1 (ICAM-1)-expression in nephritic glomeruli. Tacrolimus 0-5 Cd4 molecule Rattus norvegicus 68-71 11172433-6 2001 Activation of CD4+ cells was suppressed significantly in the FK506-treated group on postoperative day 7 compared with the untreated group (29.4% +/- 3.55% v 52.83% +/- 11.9%; P <.01). Tacrolimus 61-66 Cd4 molecule Rattus norvegicus 14-17 11172433-8 2001 Interestingly, at late acute rejection, activated CD4+ and CD8+ T cells remained at almost the same low levels as those on postoperative day 7 in the FK506-treated group. Tacrolimus 150-155 Cd4 molecule Rattus norvegicus 50-53 7532330-3 1994 However, defects in the maturation of CD4+8+ cells to CD4+8- cells and of TCR alpha beta low MHC class I+ cells to TCR alpha beta high MHC class I+ cells were observed after FK506 administration. Tacrolimus 174-179 Cd4 molecule Rattus norvegicus 38-41 7530693-2 1994 The effect of the immunosuppressant FK506 on the expression of TCR alpha beta in rat CD4- CD8- thymocytes was also examined. Tacrolimus 36-41 Cd4 molecule Rattus norvegicus 85-88 7530693-6 1994 In contrast, continuous treatment with FK506 for 7 days markedly decreased not only the percentages of CD4+ CD8- TCR alpha beta high and CD4- CD8+ TCR alpha beta high thymocytes, but also that of CD4- CD8- TCR alpha beta high thymocytes. Tacrolimus 39-44 Cd4 molecule Rattus norvegicus 103-106 7530693-6 1994 In contrast, continuous treatment with FK506 for 7 days markedly decreased not only the percentages of CD4+ CD8- TCR alpha beta high and CD4- CD8+ TCR alpha beta high thymocytes, but also that of CD4- CD8- TCR alpha beta high thymocytes. Tacrolimus 39-44 Cd4 molecule Rattus norvegicus 137-140 7530693-6 1994 In contrast, continuous treatment with FK506 for 7 days markedly decreased not only the percentages of CD4+ CD8- TCR alpha beta high and CD4- CD8+ TCR alpha beta high thymocytes, but also that of CD4- CD8- TCR alpha beta high thymocytes. Tacrolimus 39-44 Cd4 molecule Rattus norvegicus 137-140 7584489-7 1994 These results suggest that combined treatment with FK506 and GC acts complexly to decrease rat CD4+8+ thymocytes and prevents thymocyte differentiation and maturation. Tacrolimus 51-56 Cd4 molecule Rattus norvegicus 95-98 7532330-6 1994 These results suggest that the maturation of CD4-8- TCR alpha beta- MHC class I- cells to CD4+8+ TCR alpha beta low MHC class I+ cells may be FK506 resistant, whereas FK506 may interfere with the maturation of CD4+8+ TCR alpha beta low MHC class I+ thymocytes not only to CD4+8- TCR alpha beta high MHC class I+ cells but also to CD4-8+ TCR alpha beta high MHC class I+ cells. Tacrolimus 142-147 Cd4 molecule Rattus norvegicus 45-48 7532330-6 1994 These results suggest that the maturation of CD4-8- TCR alpha beta- MHC class I- cells to CD4+8+ TCR alpha beta low MHC class I+ cells may be FK506 resistant, whereas FK506 may interfere with the maturation of CD4+8+ TCR alpha beta low MHC class I+ thymocytes not only to CD4+8- TCR alpha beta high MHC class I+ cells but also to CD4-8+ TCR alpha beta high MHC class I+ cells. Tacrolimus 142-147 Cd4 molecule Rattus norvegicus 90-93 7532330-6 1994 These results suggest that the maturation of CD4-8- TCR alpha beta- MHC class I- cells to CD4+8+ TCR alpha beta low MHC class I+ cells may be FK506 resistant, whereas FK506 may interfere with the maturation of CD4+8+ TCR alpha beta low MHC class I+ thymocytes not only to CD4+8- TCR alpha beta high MHC class I+ cells but also to CD4-8+ TCR alpha beta high MHC class I+ cells. Tacrolimus 142-147 Cd4 molecule Rattus norvegicus 90-93 7532330-6 1994 These results suggest that the maturation of CD4-8- TCR alpha beta- MHC class I- cells to CD4+8+ TCR alpha beta low MHC class I+ cells may be FK506 resistant, whereas FK506 may interfere with the maturation of CD4+8+ TCR alpha beta low MHC class I+ thymocytes not only to CD4+8- TCR alpha beta high MHC class I+ cells but also to CD4-8+ TCR alpha beta high MHC class I+ cells. Tacrolimus 142-147 Cd4 molecule Rattus norvegicus 90-93 7532330-6 1994 These results suggest that the maturation of CD4-8- TCR alpha beta- MHC class I- cells to CD4+8+ TCR alpha beta low MHC class I+ cells may be FK506 resistant, whereas FK506 may interfere with the maturation of CD4+8+ TCR alpha beta low MHC class I+ thymocytes not only to CD4+8- TCR alpha beta high MHC class I+ cells but also to CD4-8+ TCR alpha beta high MHC class I+ cells. Tacrolimus 167-172 Cd4 molecule Rattus norvegicus 45-48 7532330-6 1994 These results suggest that the maturation of CD4-8- TCR alpha beta- MHC class I- cells to CD4+8+ TCR alpha beta low MHC class I+ cells may be FK506 resistant, whereas FK506 may interfere with the maturation of CD4+8+ TCR alpha beta low MHC class I+ thymocytes not only to CD4+8- TCR alpha beta high MHC class I+ cells but also to CD4-8+ TCR alpha beta high MHC class I+ cells. Tacrolimus 167-172 Cd4 molecule Rattus norvegicus 90-93 7532330-6 1994 These results suggest that the maturation of CD4-8- TCR alpha beta- MHC class I- cells to CD4+8+ TCR alpha beta low MHC class I+ cells may be FK506 resistant, whereas FK506 may interfere with the maturation of CD4+8+ TCR alpha beta low MHC class I+ thymocytes not only to CD4+8- TCR alpha beta high MHC class I+ cells but also to CD4-8+ TCR alpha beta high MHC class I+ cells. Tacrolimus 167-172 Cd4 molecule Rattus norvegicus 90-93 7532330-6 1994 These results suggest that the maturation of CD4-8- TCR alpha beta- MHC class I- cells to CD4+8+ TCR alpha beta low MHC class I+ cells may be FK506 resistant, whereas FK506 may interfere with the maturation of CD4+8+ TCR alpha beta low MHC class I+ thymocytes not only to CD4+8- TCR alpha beta high MHC class I+ cells but also to CD4-8+ TCR alpha beta high MHC class I+ cells. Tacrolimus 167-172 Cd4 molecule Rattus norvegicus 90-93 7692621-8 1993 The analysis of lymphocyte subsets proved the decrease of W3/25: OX8 ratio in both FK506- and cyclosporin-treated groups. Tacrolimus 83-88 Cd4 molecule Rattus norvegicus 58-63 7680293-6 1993 FK 506 administration reduced markedly the incidence of infiltrating TCR alpha/beta +, CD5+, CD4+, CD8+, and LFA-1 beta + cells and the expression both of MHC class II antigens and ICAM-1 on MNC, endothelial cells and thyrocytes. Tacrolimus 0-6 Cd4 molecule Rattus norvegicus 93-96 7680293-10 1993 The results are consistent with a therapeutic effect of FK 506 mediated via interference with CD4+ T lymphocyte function and adhesion molecule-dependent cytotoxic effector mechanisms. Tacrolimus 56-62 Cd4 molecule Rattus norvegicus 94-97 1702372-1 1990 The effect of administration of FK506 at 1 mg/kg body weight for 14 days on rat lymphoid tissues, especially the thymus, and recovery after discontinuation of treatment, were investigated by the immunoperoxidase technique and flow cytofluorometry using monoclonal antibodies OX6, OX7, OX8, OX18 and W3/25, reactive with rat lymphocytes. Tacrolimus 32-37 Cd4 molecule Rattus norvegicus 299-304 1702372-6 1990 Flow cytometric analysis of the thymus showed that the percentages of cells labelled positively with OX7, OX8 and W3/25 were increased with FK506 treatment, and recovered to the normal level soon after withdrawal. Tacrolimus 140-145 Cd4 molecule Rattus norvegicus 114-119 1702372-7 1990 Furthermore, the peak of fluorescence intensity of OX7+, OX8+ and W3/25+ cells showed a temporary shift to the right during FK506 treatment; however, the peak of fluorescence intensity of OX18+ cells showed a temporary shift to the left. Tacrolimus 124-129 Cd4 molecule Rattus norvegicus 66-71 34785307-2 2022 FK-506 caused a significant attenuation in the proliferation of allogeneic CD4+ T cells and IFN-gamma secreting effector functions. Tacrolimus 0-6 Cd4 molecule Rattus norvegicus 75-78